Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213466 | 0.89 | RORC (0.80) | RORCCYP3A4SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL15684251 | 0.82 | RORC (1.00) | RORCCYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL22018787 | 0.82 | RORC (0.69) | RORCCYP3A4SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL22018552 | 0.82 | RORC (0.69) | RORCCYP3A4SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL17762230 | 0.80 | RORC (1.00) | RORCCYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL15684231 | 0.80 | RORC (1.00) | RORCCYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL17762257 | 0.80 | RORC (0.83) | RORCCYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL13832073 | 0.79 | MEN1 (0.69) | RORCCYP3A4SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL13831958 | 0.79 | CYP3A4 (0.65) | RORCCYP3A4SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL17762415 | 0.78 | RORC (0.65) | RORCCYP3A4HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017268-A1 | METHODS FOR TREATING ALCOHOLIC LIVER DISEASE, ALCOHOL-INDUCED BRAIN INJURY AND REDUCING ALCOHOL ADDICTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017268-A1 | METHODS FOR TREATING ALCOHOLIC LIVER DISEASE, ALCOHOL-INDUCED BRAIN INJURY AND REDUCING ALCOHOL ADDICTION | RORB, IL17A, RORC | RORC 3/4885CYP3A4 3336/4885SMN1; SMN2 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.